Page last updated: 2024-12-08

geranyl pyrophosphate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

geranyl pyrophosphate: RN given refers to (E)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

geranyl diphosphate : The diphosphate of the polyprenol compound geraniol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID445995
CHEMBL ID41342
CHEBI ID17211
CHEBI ID55337
SCHEMBL ID109367
SCHEMBL ID109368
MeSH IDM0064355

Synonyms (43)

Synonym
gtpl3051
diphosphoric acid, mono[(2e)-3,7-dimethyl-2,6-octadienyl] ester
geranyl pyrophosphate (6ci)
2,6-octadien-1-ol, 3,7-dimethyl-, trihydrogen pyrophosphate, (e)- (8ci)
diphosphoric acid, mono[(2e)-3,7-dimethyl-2,6-octadienyl] ester (9ci)
diphosphoric acid, mono(3,7-dimethyl-2,6-octadienyl) ester, (e)-
trans-3,7-dimethyl-2,6-octadienyl pyrophosphate
763-10-0
trans-geranyl-pp
trans-geranyl pyrophosphate
pyrophosphoric acid, (e)-3,7-dimethyl-2,6-octadienyl ester
C00341
monoterpenyl diphosphate
geranyl diphosphate
geranyl pyrophosphate
GERANYL-PP ,
C05847
geranyl pyrophosphate ammonium salt, 1 mg/ml in methanol (:aqueous 10 mm nh4oh (7:3)), >=95% (tlc)
DB02552
(2e)-3,7-dimethylocta-2,6-dien-1-yl trihydrogen diphosphate
CHEBI:17211 ,
LMPR0102010001
CHEMBL41342
[(2e)-3,7-dimethylocta-2,6-dienyl] phosphono hydrogen phosphate
CHEBI:55337
unii-7x7dbm66jg
7x7dbm66jg ,
EPITOPE ID:153910
SCHEMBL109367
SCHEMBL109368
geranylpyrophosphoric acid
diphosphoric acid, p-[(2e)-3,7-dimethyl-2,6-octadien-1-yl]-
HY-114295
geranyl pyrophosphate ammonium 200
geranyl pyrophosphate ammonium*200 ug/vi al
Q418125
geranyl diphosphate (gpp)
DTXSID801315430
13100-81-7
CS-0081958
p-(3,7-dimethyl-2,6-octadien-1-yl) trihydrogen (diphosphate)
2,6-octadien-1-ol, 3,7-dimethyl-, trihydrogen pyrophosphate, (e)-
diphosphoric acid, p-(3,7-dimethyl-2,6-octadien-1-yl) ester
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (2)

RoleDescription
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (1)

ClassDescription
polyprenyl diphosphate
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (56)

PathwayProteinsCompounds
Metabolism14961108
Metabolism of lipids500463
Metabolism of steroids111135
Cholesterol biosynthesis2249
Steroid Biosynthesis2142
Smith-Lemli-Opitz Syndrome (SLOS)2142
CHILD Syndrome2142
Desmosterolosis2142
Chondrodysplasia Punctata II, X-Linked Dominant (CDPX2)2142
Lysosomal Acid Lipase Deficiency (Wolman Disease)2142
Ibandronate Action Pathway2143
Simvastatin Action Pathway2143
Pravastatin Action Pathway2143
Rosuvastatin Action Pathway2143
Alendronate Action Pathway2143
Hypercholesterolemia2142
Lovastatin Action Pathway2143
Zoledronate Action Pathway2143
Cerivastatin Action Pathway2143
Risedronate Action Pathway2143
Pamidronate Action Pathway2143
Fluvastatin Action Pathway2143
Atorvastatin Action Pathway2143
Cholesteryl Ester Storage Disease2142
Hyper-IgD Syndrome2142
Mevalonic Aciduria2142
Wolman Disease2142
Secondary Metabolites: Methylerythritol Phosphate and Polyisoprenoid Biosynthesis1121
Terpenoid Backbone Biosynthesis1322
Cholesterol biosynthesis and metabolism CE(14:0)2250
Cholesterol biosynthesis and metabolism CE(10:0)2250
Cholesterol Biosynthesis and Metabolism CE(12:0)2250
Cholesterol Biosynthesis and Metabolism CE(16:0)2250
Cholesterol biosynthesis and metabolism CE(18:0)2250
Epoxysqualene Biosynthesis612
Farnesene Biosynthesis68
Monoterpenoid Biosynthesis618
Steroids metabolism ( Steroids metabolism )1627
Cholesterol metabolism with Bloch and Kandutsch-Russell pathways039
Cholesterol Biosynthesis and Metabolism2248
Mevalonate Pathway1126
MEP/DOXP Pathway819
Cholesterol synthesis disorders015
Mevalonate pathway010
Cholesterol biosynthesis pathway in hepatocytes1137
Ergosterol biosynthesis332
superpathway of sterol biosynthesis050
trans, trans-farnesyl diphosphate biosynthesis I05
Geranylgeranyldiphosphate biosynthesis II (plastidic)03
Biochemical pathways: part I0466
GPP biosynthesis04
FPP biosynthesis05
GGPP biosynthesis II (plastidic)06
Myrcene biosynthesis013
Oleoresin monoterpene volatiles biosynthesis09
Polyisoprenoid biosynthesis06
Secologanin and strictosidine biosynthesis015

Bioassays (9)

Assay IDTitleYearJournalArticle
AID1145975Inhibition of Baker's yeast squalene synthetase assessed as incorporation of [1-3H]farnesyl pyrophosphate into squalene up to 20 uM after 2 mins by liquid scintillation spectrometer analysis1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of squalene synthetase by farnesyl pyrophosphate analogues.
AID1829588Inhibition of human SHIP2 catalytic domain (419 to 832 residues) phosphatase activity assessed as phosphate release using Ins(1,3,4,5)P4 as substrate at 1 mM incubated for 20 mins measured using microplate reader2021Journal of medicinal chemistry, 04-08, Volume: 64, Issue:7
Allosteric Site on SHIP2 Identified Through Fluorescent Ligand Screening and Crystallography: A Potential New Target for Intervention.
AID1145974Inhibition of Baker's yeast squalene synthetase assessed as incorporation of [1-3H]farnesyl pyrophosphate into squalene at 2 to 6 uM after 2 mins by liquid scintillation spectrometer analysis1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of squalene synthetase by farnesyl pyrophosphate analogues.
AID1751938Binding affinity to Burkholderia pseudomallei IspF by STD NMR analysis2021Bioorganic & medicinal chemistry letters, 09-15, Volume: 48Structural and biophysical characterization of the Burkholderia pseudomallei IspF inhibitor L-tryptophan hydroxamate.
AID1145973Competitive inhibition of Baker's yeast squalene synthetase using [1-3H]farnesyl pyrophosphate as substrate by Lineweaver-Burk graphic analysis1977Journal of medicinal chemistry, Feb, Volume: 20, Issue:2
Inhibition of squalene synthetase by farnesyl pyrophosphate analogues.
AID1346896Rat mevalonate kinase (Lanosterol biosynthesis pathway)2006Organic letters, Mar-16, Volume: 8, Issue:6
Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase.
AID1346808Rat diphosphomevalonate decarboxylase (Lanosterol biosynthesis pathway)2006Organic letters, Mar-16, Volume: 8, Issue:6
Bifunctional inhibitors of mevalonate kinase and mevalonate 5-diphosphate decarboxylase.
AID1346808Rat diphosphomevalonate decarboxylase (Lanosterol biosynthesis pathway)2006Biochimica et biophysica acta, Jul, Volume: 1760, Issue:7
Inhibition of mevalonate 5-diphosphate decarboxylase by fluorinated substrate analogs.
AID1346823Human mevalonate kinase (Lanosterol biosynthesis pathway)1997Journal of lipid research, Nov, Volume: 38, Issue:11
Post-translational regulation of mevalonate kinase by intermediates of the cholesterol and nonsterol isoprene biosynthetic pathways.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (182)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (17.03)18.7374
1990's16 (8.79)18.2507
2000's40 (21.98)29.6817
2010's73 (40.11)24.3611
2020's22 (12.09)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 54.51

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index54.51 (24.57)
Research Supply Index5.21 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index87.95 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (54.51)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (2.73%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other178 (97.27%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]